Company
Headquarters: New Taipei City, Taiwan
CEO: Dr. Mei-Chun Yang
TW$2.66 Billion
TWD as of Jan. 1, 2025
US$81.1 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $113.24 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $76.33 B |
Marinomed Biotech AG | $56.13 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
GlycoNex Incorporation develops cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. Its technology platform enables glycosphingolipid antigen production and identification; monoclonal antibody production; cancer drug screening; stable cell line production for monoclonal antibody; and pharmacology/pharmacokinetics assessment. The company offers GNX102, a humanized antibody for cancer-specific glycan prevalent on several types of cancer cells, such as gastric, colon, and pancreatic cancer, as well as develops bi-specific antibody generate armed T-cells targeting glycan antigens on cancer cells. GlycoNex Incorporation was founded in 2001 and is based in New Taipei City, Taiwan.
GlycoNex InCorp has the following listings and related stock indices.
Stock: TWSE: 4168 wb_incandescent